Final analysis of the POLO trial showed that, although overall survival (OS) did not reach statistical significance, the treatment extended the chemotherapy-free interval and improved survival rates ( 66 ).
← all excerpts
DNA damage response inhibitors in pancreatic cancer: progress and challenges.
1
—
—